Inactive Instrument

Sophiris Bio, Inc. Stock price Other OTC

Equities

SPHS

CA83578Q2099

Dynamic Chart
Swiss franc rises to six year high as central bank stands back RE
Sophiris Bio : Swiss c.bank diverges from peers to stick with ultra-loose monetary course RE
Transcript : Sophiris Bio, Inc. - Special Call
Transcript : Sophiris Bio, Inc. - Special Call
Sophiris Bio, Inc. Announces Joseph L. Turner Would Not Be Stand for Re-Election at the Annual General Meeting CI
Sophiris Bio, Inc. Auditor Raises 'Going Concern' Doubt CI
Sophiris Bio, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015 CI
Sophiris Bio, Inc. Reports Encouraging Preliminary Data from Phase 2A Proof of Concept Study in Localized Prostate Cancer CI
Sophiris Bio, Inc. announced that it has received $2.8 million in funding from Aspire Capital Partners, LLC CI
Sophiris Bio, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015 CI
Sophiris Bio Phase 3 BPH Study Successfully Meets Primary Endpoint CI
Sophiris Bio, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015 CI
Sophiris Bio, Inc. Enrolls First Patients in Phase 2a Proof of Concept Prostate Cancer Study CI
Sophiris Bio Inc. Announces Unaudited Consolidated Financial Results for the Three Months Ended March 31, 2015 CI
Sophiris Bio, Inc. Announces Unaudited Consolidated Cash Flow Results for the Year Ended December 31, 2014 CI
More news
Sophiris Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of urological diseases. The Company is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer. Topsalysin, a genetically modified recombinant protein, is delivered through ultrasound-guided injection directly into the prostate. This membrane-disrupting protein is selectively activated by enzymatically active prostate specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. This method of administration limits the circulation of the drug in the body. The Company has completed Phase III clinical trials of topsalysin.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock Sophiris Bio
  4. Stock Sophiris Bio, Inc. - Other OTC